UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA

Clinical rheumatology, 2018-02, Vol.37 (2), p.315-321

2018

Volltextzugriff (PDF)

Is there really room for anti-rheumatic drugs in the treatment of COVID-19?

Scandinavian journal of rheumatology, 2020-09, Vol.49 (5), p.412-413

2020

Volltextzugriff (PDF)

POS0048 SEROPREVALENCE OF ANTI-SARS-COV-2 ANTIBODIES IN RHEUMATIC PATIENTS TREATED WITH BIOLOGICAL AND TARGETED THERAPY LIVING IN LOMBARDY, ITALY (MAINSTREAM PROJECT)

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.229-229

2021

Volltextzugriff (PDF)

POS0675 THE COMPARATIVE 3-YEAR RETENTION RATE OF TARGETED-SYNTHETIC AND BIOLOGIC DRUGS FOR RHEUMATOID ARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN GISEA REGISTRY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.582-582

2021

Volltextzugriff (PDF)

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

Reumatismo, 2023-07, Vol.75 (2)

2023

Volltextzugriff (PDF)

SAT0132 Comorbidities affect the retention rate but not the clinical response in a cohort of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.928

2018

Volltextzugriff (PDF)

Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy

Clinical and experimental rheumatology, 2008-01, Vol.26 (1), p.45

2008

Volltextzugriff (PDF)

Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy

Clinical and experimental rheumatology, 2005-03, Vol.23 (2), p.247

2005

Volltextzugriff (PDF)

SAT0223 Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.972

2018

Volltextzugriff (PDF)

THU0151 Disease Duration and Year of Publication Affect the Results of Studies on Rheumatoid Arthritis Damage Progression by Biologic Agents: A Systematic Review and Meta-Analysis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A214-A214

2013

Volltextzugriff (PDF)

FRI0229 Survival on treatment of the second line biologic therapy: switch or swap strategy?

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A450-A451

2013

Volltextzugriff (PDF)

POS0479 ANALYSIS OF TEMPORAL TRAJECTORIES AND DEFINITION CRITERIA SUSTAINING PERSISTENCE OF THE DIFFICULT-TO-TREAT STATUS OF RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A SINGLE-CENTER, REAL-LIFE STUDY

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.849-850

2024

Volltextzugriff (PDF)

OP0201 REASONS FOR TREATMENT FAILURE: A COMPARISON BETWEEN “MULTI-REFRACTORY” AND “DIFFICULT-TO-TREAT” RHEUMATOID ARTHRITIS PATIENTS

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.102-103

2024

Volltextzugriff (PDF)

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis

Lupus, 2002-01, Vol.11 (11), p.753-755

2002

Volltextzugriff (PDF)

AB1475 ELDERLY ONSET RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: A COMPARATIVE STUDY OF TWO CONSECUTIVE COHORTS

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.2102-2103

2024

Volltextzugriff (PDF)

POS0024 RETENTION RATE OF TNF INHIBITORS (TNFI), ANTI-IL17, AND ANTI-IL12/23 DRUGS IN A SINGLE-CENTER COHORT OF PSORIATIC ARTHRITIS PATIENTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.218-218

2023

Volltextzugriff (PDF)

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

Rheumatology (Oxford, England), 2014-09, Vol.53 (9), p.1664-1668

2014

Volltextzugriff (PDF)

AB0671 PREVALENCE OF EXTRA-ARTICULAR MANIFESTATIONS AND IMPACT ON TARGETED DRUG PRESCRIPTION IN PATIENTS WITH SPONDYLOARTHRITIS: A RETROSPECTIVE ANALYSIS OF A REAL-LIFE COHORT

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.1630-1631

2020

Volltextzugriff (PDF)

OP0061 TIGHT CONTROL IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TARGETED THERAPIES ACROSS THE COVID-19 PANDEMIC ERA

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.42-42

2022

Volltextzugriff (PDF)

POS0607 IMPROVING TREAT-TO-TARGET IMPLEMENTATION IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW OF BARRIERS, FACILITATORS, AND INTERVENTIONS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.572-572

2022

Volltextzugriff (PDF)

POS0943 EFFECT OF NERIDRONATE ON AXIAL SPONDYLOARTHRITIS WHEN bDMARDs ARE NOT AN OPTION: RESULTS FROM A RESTROSPECTIVE STUDY

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.775-776

2022

Volltextzugriff (PDF)

AB0463 THE IMPACT OF PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) RECOMMENDATIONS ON THE REAL-LIFE USE OF JANUS KINASES INHIBITORS FOR RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1423-1424

2023

Volltextzugriff (PDF)

AB0989 ARE OSTEOPOROSIS AND FRACTURES NEGLECTED ISSUES IN AXIAL SPONDYLOARTHRITIS? DATA FROM A CROSS-SECTIONAL MONOCENTRIC STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1715-1715

2023

Volltextzugriff (PDF)

POS0545 PRE-EXPOSURE PROPHYLAXIS OF COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB: DATA FROM A SINGLE-CENTRE COHORT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.537-538

2023

Volltextzugriff (PDF)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

ClinicoEconomics and outcomes research, 2017-01, Vol.9, p.9-17

2017

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(205)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA

Is there really room for anti-rheumatic drugs in the treatment of COVID-19?

POS0048 SEROPREVALENCE OF ANTI-SARS-COV-2 ANTIBODIES IN RHEUMATIC PATIENTS TREATED WITH BIOLOGICAL AND TARGETED THERAPY LIVING IN LOMBARDY, ITALY (MAINSTREAM PROJECT)

POS0675 THE COMPARATIVE 3-YEAR RETENTION RATE OF TARGETED-SYNTHETIC AND BIOLOGIC DRUGS FOR RHEUMATOID ARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN GISEA REGISTRY

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

SAT0132 Comorbidities affect the retention rate but not the clinical response in a cohort of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors

Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy

Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy

SAT0223 Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry

THU0151 Disease Duration and Year of Publication Affect the Results of Studies on Rheumatoid Arthritis Damage Progression by Biologic Agents: A Systematic Review and Meta-Analysis

FRI0229 Survival on treatment of the second line biologic therapy: switch or swap strategy?

POS0479 ANALYSIS OF TEMPORAL TRAJECTORIES AND DEFINITION CRITERIA SUSTAINING PERSISTENCE OF THE DIFFICULT-TO-TREAT STATUS OF RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A SINGLE-CENTER, REAL-LIFE STUDY

OP0201 REASONS FOR TREATMENT FAILURE: A COMPARISON BETWEEN “MULTI-REFRACTORY” AND “DIFFICULT-TO-TREAT” RHEUMATOID ARTHRITIS PATIENTS

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis

AB1475 ELDERLY ONSET RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: A COMPARATIVE STUDY OF TWO CONSECUTIVE COHORTS

POS0024 RETENTION RATE OF TNF INHIBITORS (TNFI), ANTI-IL17, AND ANTI-IL12/23 DRUGS IN A SINGLE-CENTER COHORT OF PSORIATIC ARTHRITIS PATIENTS

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

AB0671 PREVALENCE OF EXTRA-ARTICULAR MANIFESTATIONS AND IMPACT ON TARGETED DRUG PRESCRIPTION IN PATIENTS WITH SPONDYLOARTHRITIS: A RETROSPECTIVE ANALYSIS OF A REAL-LIFE COHORT

OP0061 TIGHT CONTROL IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TARGETED THERAPIES ACROSS THE COVID-19 PANDEMIC ERA

POS0607 IMPROVING TREAT-TO-TARGET IMPLEMENTATION IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW OF BARRIERS, FACILITATORS, AND INTERVENTIONS

POS0943 EFFECT OF NERIDRONATE ON AXIAL SPONDYLOARTHRITIS WHEN bDMARDs ARE NOT AN OPTION: RESULTS FROM A RESTROSPECTIVE STUDY

AB0463 THE IMPACT OF PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) RECOMMENDATIONS ON THE REAL-LIFE USE OF JANUS KINASES INHIBITORS FOR RHEUMATOID ARTHRITIS

AB0989 ARE OSTEOPOROSIS AND FRACTURES NEGLECTED ISSUES IN AXIAL SPONDYLOARTHRITIS? DATA FROM A CROSS-SECTIONAL MONOCENTRIC STUDY

POS0545 PRE-EXPOSURE PROPHYLAXIS OF COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB: DATA FROM A SINGLE-CENTRE COHORT

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

Suchergebnisse filtern